| Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial BA Wilky, MM Trucco, TK Subhawong, V Florou, W Park, D Kwon, ... The lancet oncology 20 (6), 837-848, 2019 | 324 | 2019 |
| Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution V Florou, AE Rosenberg, E Wieder, KV Komanduri, D Kolonias, ... Journal for immunotherapy of cancer 7, 1-8, 2019 | 171 | 2019 |
| Current and future directions for angiosarcoma therapy V Florou, BA Wilky Current treatment options in oncology 19, 1-13, 2018 | 106 | 2018 |
| Considerations for treatment duration in responders to immune checkpoint inhibitors TU Marron, AE Ryan, SM Reddy, S Kaczanowska, RH Younis, D Thakkar, ... Journal for immunotherapy of cancer 9 (3), 2021 | 88 | 2021 |
| Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort AR Naqash, B Ricciuti, DH Owen, V Florou, Y Toi, C Cherry, M Hafiz, ... Cancer Immunology, Immunotherapy 69, 1177-1187, 2020 | 78 | 2020 |
| Clinical and immunological implications of frameshift mutations in lung cancer YK Chae, P Viveiros, G Lopes, B Sukhadia, MM Sheikh, D Saravia, ... Journal of Thoracic Oncology 14 (10), 1807-1817, 2019 | 35 | 2019 |
| Current management of angiosarcoma: recent advances and lessons from the past V Florou, BA Wilky Current Treatment Options in Oncology 22 (7), 61, 2021 | 27 | 2021 |
| Therapeutic strategies for pigmented purpuric dermatoses: a systematic literature review KM Plachouri, V Florou, S Georgiou Journal of Dermatological Treatment 30 (2), 105-109, 2019 | 26 | 2019 |
| Clinical activity of selitrectinib in a patient with mammary analogue secretory carcinoma of the parotid gland with secondary resistance to entrectinib V Florou, C Nevala-Plagemann, J Whisenant, P Maeda, GW Gilcrease, ... Journal of the National Comprehensive Cancer Network 19 (5), 478-482, 2021 | 22 | 2021 |
| Safety and activity of immune checkpoint inhibitors in people living with HIV and cancer: A real-world report from the cancer therapy using checkpoint inhibitors in people … T El Zarif, AH Nassar, E Adib, BG Fitzgerald, J Huang, TH Mouhieddine, ... Journal of Clinical Oncology 41 (21), 3712-3723, 2023 | 20 | 2023 |
| Models for mature T-cell lymphomas—a critical appraisal of experimental systems and their contribution to current T-cell tumorigenic concepts K Warner, G Crispatzu, N Al-Ghaili, N Weit, V Florou, MJ You, S Newrzela, ... Critical Reviews in Oncology/Hematology 88 (3), 680-695, 2013 | 20 | 2013 |
| Clinical development of anti-TIGIT antibodies for immunotherapy of cancer V Florou, I Garrido-Laguna Current Oncology Reports 24 (9), 1107-1112, 2022 | 18 | 2022 |
| Updated dose escalation results for ReFocus, a first-in-human study of highly selective FGFR2 inhibitor RLY-4008 in cholangiocarcinoma and other solid tumors MJ Borad, AM Schram, RD Kim, SD Kamath, V Sahai, E Dotan, RK Kelley, ... J Clin Oncol 41 (suppl 16), 4009, 2023 | 17 | 2023 |
| Global health perspective in sarcomas and other rare cancers V Florou, AG Nascimento, A Gulia, G de Lima Lopes Jr American Society of Clinical Oncology Educational Book 38, 916-924, 2018 | 14 | 2018 |
| Precision medicine in gastrointestinal stromal tumors V Florou, JC Trent, BA Wilky Discovery medicine 28 (155), 267-276, 2019 | 13 | 2019 |
| A phase II trial of axitinib plus pembrolizumab for patients with advanced alveolar soft part sarcoma (ASPS) and other soft tissue sarcomas (STS). BA Wilky, MM Trucco, D Kolonias, E Wieder, T Subhawong, A Rosenberg, ... Journal of clinical oncology 36 (15_suppl), 11547-11547, 2018 | 13 | 2018 |
| The emerging landscape of immune checkpoint inhibitor based clinical trials in adults with advanced rare tumors A Mittra, N Takebe, V Florou, AP Chen, AR Naqash Human Vaccines & Immunotherapeutics 17 (7), 1935-1939, 2021 | 11 | 2021 |
| Comparative genomic analysis of pancreatic acinar cell carcinoma (PACC) and pancreatic ductal adenocarcinoma (PDAC) unveils new actionable genomic aberrations in PACC V Florou, A Elliott, MH Bailey, D Stone, K Affolter, HP Soares, ... Clinical Cancer Research 29 (17), 3408-3417, 2023 | 10 | 2023 |
| Discrepancies between tumor genomic profiling and germline genetic testing K Pauley, C Koptiuch, S Greenberg, W Kohlmann, J Jeter, S Colonna, ... ESMO open 7 (4), 100526, 2022 | 10 | 2022 |
| Considerations for immunotherapy in patients with cancer and comorbid immune dysfunction V Florou, S Puri, I Garrido-Laguna, BA Wilky Annals of Translational Medicine 9 (12), 2021 | 10 | 2021 |
